Effect of methamphetamine on cytochrome P450 activity

References

• Agrawal AK, Shapiro BH. Constitutive and inducible hepatic P450 isoforms in senescent male and female rats and response to low-dose phenobarbital. Drug Metabolism and Disposition 2003; 31(5)612–619
   PubMed Web of Science ®Google Scholar
• Allen TS, Kiser WO. Methamphetamine from ephedrine: 1 Chloroephedrine andaziridines. Journal of Forensic Sciences 1987; 32(12)953–962
   Google Scholar
• Anglin MD, Burke C, Perrochet B, Stamper E, Wud-Noursi S. History of the methamphetamine problem. Journal Psychoactive Drugs 2000; 32(2)137–141
   PubMed Web of Science ®Google Scholar
• Anzenbacher P, Anzenbacherova E. Cytochrome P450 and metabolism of xenobiotic. Cellular and Molecular Life Sciences 2001; 58(5–6)737–747
   PubMed Web of Science ®Google Scholar
• Baba T, Yamada H, Oguri K, Yoshimura H. Participation of cytochrome P-450 isozymes in N-demethylation, N-hydroxylation and aromatic hydroxylation of methamphetamine. Xenobiotica 1988; 18(5)475–484
   PubMed Web of Science ®Google Scholar
• Barr AM, Panenka WJ, MacEwa GW, Thorton AE, Lang DJ, Honer WG, Lemonte T. The need for speed: an update on methamphetamine addiction. Journal of Neuropsychiatry and Clinical Neurosciences 2006; 31(5)301–131
   Google Scholar
• Caldwell J, Dring LG, Williams RT. Metabolism of (14 C) methamphetamine in man, the guinea pig and the rat. Biochemical Journal 1972; 129(1)11–22
   PubMed Web of Science ®Google Scholar
• Cantrell TS, John B, Johnson L, Allen AC. A study of impurities found in methamphetamine synthesized from ephedrine. Forensic Science International 1988; 39(2–3)39–53
   Google Scholar
• Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metabolism Disposition 1995; 23(3)406–414
   PubMed Web of Science ®Google Scholar
• Derlet RW, Heischober B. Methamphetamine Stimulant of the 1.990s?. Western Journal of Medicine 1990; 153(6)625–628
   PubMedGoogle Scholar
• Dostalek M, Hadasova E, Hanesova M, Pisvotcakova J, Sulcova A, Jurica J, Tomandl J, Linhart I. Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats. European Journal of Drug Metabolism and Pharmacokinetics 2005a; 30(3)195–201
   PubMed Web of Science ®Google Scholar
• Dostalek M, Jurica J, Janostikova E, Zahradnikova L. Pharmacokinetics. Grada, Prague 2006
   Google Scholar
• Dostalek M, Pistovcakova J, Jurica J, Tomandl J, Linhart I, Sulcova A, Hadasova E. Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver. Life Sciences 2005b; 78(3)239–244
   PubMed Web of Science ®Google Scholar
• Edmunds-Ogbuokiri T. How common illicit substances interact with antiretroviral agents. HIV Clinician 2003; 1.5(1)6–7
   Google Scholar
• Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. The Journal of Pharmacology and Experimental Therapeutics 2005; 3.12(2)583–591
   Google Scholar
• Gilman AG, Rall TW, Nies AS, Taylor P. Goodman and Gillman's the pharmacological basis of therapeutics, 8th edn. Pergamon, New York, NY 1990
   Google Scholar
• Goldstein DJ, Ramper DJ, Potvin JH, Masica DN, Beasley CM. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. Journal of Clinical Psychiatry 1993; 54(8)309–316
   PubMed Web of Science ®Google Scholar
• Greenway F, Herber D, Raum W, Herber D, Morales D, Morales S. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. Obesity Research 1999; 7(4)370–398
   PubMedGoogle Scholar
• Guengerich FP. Human cytochrome P450 enzymes. Cytochrome P450: structure, mechanisms and biochemistry, PR Ortiz de Montellano. Plenum, New York, NY 1995; 473–535
   Google Scholar
• Guengerich FP. Comparisons on catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chemico-Biological Interactions 1997a; 106(3)161–182
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Role of cytochrome P450 in drug–drug interactions. Advances in Pharmacology 1997b; 43: 7–35
   PubMedGoogle Scholar
• Hales G, Roth G, Smith D. Possible fatal interaction between protease inhibitors and methamphetamine. Antiviral Therapy 2000; 5(1)1–19
   Google Scholar
• Hoen PA, Bijsterbosch MK, Van Berkel TJ, Vermeulen NP, Commandeur JN. Midazolam is a phenobarbital-like cytochrome p450 inductor in rats. Journal of Pharmacology and Experimental Therapeutics 2001; 299(3)921–927
   PubMed Web of Science ®Google Scholar
• Kiorbe E. Drug therapy of epilepsy. Preparations II. Nordisk Medicin 1965; 73: 291–293
   PubMedGoogle Scholar
• Kobayashi K, Urashima K, Shimada N, Chiba K. Substrate specifity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed system of the rat. Biochemical Pharmacology 2002; 63(5)889–896
   PubMed Web of Science ®Google Scholar
• Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, Greenblath DJ. In vitro, pharmacokinetic and pharmacodynamic interactions of ketoconazole and midazolam in the rat. Journal of Pharmacology and Experimental Therapeutics 2002; 302(3)1228–1237
   PubMed Web of Science ®Google Scholar
• Lau CE, Ma F, Wang Y, Smith C. Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. Psychopharmacology 1996; 126(3)241–248
   PubMed Web of Science ®Google Scholar
• Logothetis J. Methamphetamine sulfate in the treatment of nocturnal epileptic seizures. Minnesota Medicine 1959; 42(3)248–249
   PubMedGoogle Scholar
• Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‘Ecstasy’). Toxicology Letters 2000; 112–113: 133–142
   PubMed Web of Science ®Google Scholar
• Nebert DW, McKinnon RA. P450: evolution and functional diversity. Progress in Liver Diseases 1994; 12: 63–97
   PubMedGoogle Scholar
• Nelson DR. Cytochrome P450 and the individuality of species. Archives of Biochemistry and Biophysics 1999; 369(1)1–10
   PubMed Web of Science ®Google Scholar
• Nelson DR, Koymans L, Katamaki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6(1)1–42
   PubMedGoogle Scholar
• Newton TF, Roache JD, De La Garza R, II, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology 2005; 182(3)426–435
   PubMed Web of Science ®Google Scholar
• Newton TF, Roache JD, De La Garza R, II, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006; 31(7)1537–1544
   PubMed Web of Science ®Google Scholar
• Noda Y, Nabeshima Y. Behavioral assessment of neuroleptics (3) — schizophrenia negative symptoms-like model induced by PCP. Japanese Journal of Psychopharmacology 1996; 16(4)123–128
   Google Scholar
• Omiecinski CJ, Hassett C, Costa P. Developmental expression and in situ localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1, CYP2B2, CYP2C6, and CYP3A1. Molecular Pharmacology 1990; 38(4)462–470
   PubMed Web of Science ®Google Scholar
• Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. American Journal of Therapeutics 2004; 11(4)262–277
   PubMedGoogle Scholar
• Peters FT, Samyn N, Wahl M, Kraemer T, De Boeck G, Maurer HH. Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. Journal of Analytical Toxicology 2003; 27(8)552–559
   PubMed Web of Science ®Google Scholar
• Phillips TR, Bilaud JN, Henriksen SJ. Methamphetamine and HIV-1: potential interactions and the use of the FIV/cat model. Journal of Psychopharmacology 2004; 14(3)244–250
   Google Scholar
• Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 2003; 15(1)775–785
   PubMed Web of Science ®Google Scholar
• Rege B, Carter KM, Sarkar MA, Kellogg GE, Soine WH. Irreversible inhibition of CYP2D6 by (–)-chloroephedrine, a possible impurity in methamphetamine. Drug Metabolism and Disposition 2002; 30(12)1337–1343
   PubMed Web of Science ®Google Scholar
• Semple SJ, Patterson TL, Grant I. Motivations associated with methamphetamine use among HIV + men who have sex with men. Journal of Substance Abuse Treatment 2002; 22(3)149–156
   PubMed Web of Science ®Google Scholar
• Skinner HF. Methamphetamine synthesis via hydriodic acid/red phosphorous reduction of ephedrine. Forensic Science International 1990; 48(2)123–134
   Google Scholar
• Smith D, Hales D, Roth N, Law M, Ray J, Druett J, Mitchell J, Mills G, Dooing N, Franklin R. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. HIV Clinical Trials 2001; 2(2)97–107
   PubMedGoogle Scholar
• Tanaka K, Ohmori T, Inoue T. Analysis of impurities in illicit methamphetamine. Forensic Science International 1992; 56(1)157–165
   Google Scholar
• Williams MT, Moran MS, Vorhess CV. Behavioral and growth effects induced by low dose methamphetamine administration during the neonatal period in rats. International Journal of Developmental Neuroscience 2004; 22(5–6)273–283
   PubMed Web of Science ®Google Scholar
• Wu D, Otto SV, Inaba T, Kalow W, Sallers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochemical Pharmacology 1997; 53(11)1605–1612
   PubMed Web of Science ®Google Scholar
• Zive JL, Leonard J. Creating a friendly environment for your HIV medications The effect of interactions. Positively Aware 2005; 32: 16–21
   Google Scholar